LT5058B - Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui - Google Patents

Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui Download PDF

Info

Publication number
LT5058B
LT5058B LT2002063A LT2002063A LT5058B LT 5058 B LT5058 B LT 5058B LT 2002063 A LT2002063 A LT 2002063A LT 2002063 A LT2002063 A LT 2002063A LT 5058 B LT5058 B LT 5058B
Authority
LT
Lithuania
Prior art keywords
metformin
glyburide
dose
combination
low
Prior art date
Application number
LT2002063A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002063A (en
Inventor
Beth Anne Piper
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2002063A publication Critical patent/LT2002063A/xx
Publication of LT5058B publication Critical patent/LT5058B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LT2002063A 1999-11-03 2002-05-24 Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui LT5058B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (2)

Publication Number Publication Date
LT2002063A LT2002063A (en) 2003-06-25
LT5058B true LT5058B (lt) 2003-09-25

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002063A LT5058B (lt) 1999-11-03 2002-05-24 Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui

Country Status (23)

Country Link
EP (1) EP1229918B1 (et)
JP (1) JP5183844B2 (et)
KR (1) KR20070089259A (et)
CN (1) CN1450902A (et)
AR (1) AR026356A1 (et)
AT (1) ATE390140T1 (et)
AU (1) AU780106B2 (et)
BR (1) BR0015294A (et)
CA (1) CA2389928C (et)
EE (1) EE05260B1 (et)
HU (1) HU229352B1 (et)
IL (1) IL149139A0 (et)
LT (1) LT5058B (et)
LV (1) LV12910B (et)
MX (1) MXPA02004282A (et)
NO (1) NO330026B1 (et)
NZ (1) NZ518278A (et)
PL (1) PL199278B1 (et)
RU (1) RU2275915C2 (et)
SK (1) SK287810B6 (et)
TW (1) TWI280125B (et)
UY (1) UY26424A1 (et)
WO (1) WO2001032157A2 (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7442720B2 (en) 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
CN1976691B (zh) * 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
US8900638B2 (en) 2007-07-19 2014-12-02 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
ES2647504T3 (es) 2007-09-10 2017-12-21 Janssen Pharmaceutica N.V. Proceso para la preparación de compuestos útiles como inhibidores de SGLT
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
LT2611458T (lt) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
MX2013008484A (es) * 2011-02-02 2013-08-12 Sanofi Aventis Deutschland Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
EP0749751A2 (en) 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
US5631224A (en) 1992-03-19 1997-05-20 Novo Nordisk A/S Use of a peptide
WO1997017975A1 (en) 1995-11-14 1997-05-22 Abiogen Pharma S.R.L. A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
EP0974356A1 (en) 1998-07-15 2000-01-26 Lipha Tablets comprising a combination of metformin and glibenclamide
US9353141B2 (en) 2012-01-25 2016-05-31 Galecto Biotech Ab Galectoside inhibitors of galectins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US5631224A (en) 1992-03-19 1997-05-20 Novo Nordisk A/S Use of a peptide
EP0749751A2 (en) 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
WO1997017975A1 (en) 1995-11-14 1997-05-22 Abiogen Pharma S.R.L. A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
EP0974356A1 (en) 1998-07-15 2000-01-26 Lipha Tablets comprising a combination of metformin and glibenclamide
US9353141B2 (en) 2012-01-25 2016-05-31 Galecto Biotech Ab Galectoside inhibitors of galectins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CROUSE ET AL.: "Effects of combination of glipizide/metformin treatment on oxidizability of LLD in NIDDIM", CIRCULATION, 1996, pages 1508
EDWARDS ET AL.: "Combination of glipizide/metformin treatment reduces low density lipoprotein binding to arterial proteoglycans in DIDDM", DIABETES, 1997, pages 46
HIGINBOTHAM ET AL.: "Dauble-Blind Trial of Metformin in the Therapy of Non-Ketotic Diadetes", THE MED. JOURNAL OF AUSTRALIA, 1979, pages 154 - 156
VIGNERI ET AL.: "Treatment of NIDDM Patients with Secondary Failure to Glyburide", DIABETE & METABOLISME, 1991, pages 232 - 234, XP000570538

Also Published As

Publication number Publication date
HU229352B1 (en) 2013-11-28
SK5002002A3 (en) 2004-05-04
AU1082601A (en) 2001-05-14
EP1229918A2 (en) 2002-08-14
IL149139A0 (en) 2002-11-10
CA2389928A1 (en) 2001-05-10
KR20070089259A (ko) 2007-08-30
JP2003519621A (ja) 2003-06-24
NO20022087L (no) 2002-06-24
CA2389928C (en) 2010-03-23
CN1450902A (zh) 2003-10-22
SK287810B6 (sk) 2011-10-04
TWI280125B (en) 2007-05-01
LT2002063A (en) 2003-06-25
WO2001032157A3 (en) 2002-01-24
LV12910B (en) 2003-05-20
HUP0300218A2 (hu) 2003-06-28
MXPA02004282A (es) 2003-02-17
EP1229918B1 (en) 2008-03-26
ATE390140T1 (de) 2008-04-15
NO20022087D0 (no) 2002-05-02
RU2002114820A (ru) 2004-03-10
JP5183844B2 (ja) 2013-04-17
NZ518278A (en) 2004-10-29
NO330026B1 (no) 2011-02-07
UY26424A1 (es) 2001-05-31
EE05260B1 (et) 2010-02-15
EE200200242A (et) 2003-12-15
HUP0300218A3 (en) 2006-02-28
PL364885A1 (en) 2004-12-27
BR0015294A (pt) 2003-07-15
AR026356A1 (es) 2003-02-05
WO2001032157A2 (en) 2001-05-10
PL199278B1 (pl) 2008-09-30
AU780106B2 (en) 2005-03-03
RU2275915C2 (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
US7598262B2 (en) Method for treating diabetes
LT5058B (lt) Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui
US7507768B2 (en) Antidiabetic formulation and method
JP2003519621A5 (et)
AU8022900B2 (et)

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20201013